不可切除局部晚期胰腺癌转化手术后的生存预后因素:日本全国性研究
本研究基于日本84家机构465例接受转化手术的不可切除局部晚期胰腺癌患者,发现术前治疗>6个月、FOLFIRINOX方案、肿瘤标志物正常及预后营养指数≥45是独立预后因素。具备≥3个因素者5年生存率59.8%,显著优于≤2个因素者的26.3%。
要点
- 术前治疗>6个月与更长总生存和無复发生存相关
- 四个术前因素可对转化手术患者进行风险分层
- FFX方案、肿瘤标志物正常、PNI≥45均为有利因素
核心结论
- 四个术前预后因素组合可对不可切除局部晚期胰腺癌转化手术患者进行风险分层。
研究设计与样本
- 多中心回顾性研究,纳入2015至2020年日本84家机构465例接受转化手术的不可切除局部晚期胰腺癌患者。
主要发现
- 从治疗开始的中位总生存为43.8个月,5年生存率为37.2%。
- 术前治疗>6个月者(n=350)总生存50.4个月 vs 29.7个月,无复发生存15.6个月 vs 9.1个月,均P<0.001。
- 多因素分析确定四个独立术前预后因素:治疗时长>6个月、FFX方案、CA19-9和CEA正常、转化术前PNI≥45。
- 具备≥3个因素者较≤2个因素者生存显著改善(HR 0.44,P<0.0001;5年OS 59.8% vs 26.3%)。
关键数值与推荐
- 术前治疗时长预后截断值为6.1个月(基于最大选择秩统计量)。
- 有利因素:治疗>6个月、FFX方案、CA19-9和CEA正常、转化术前PNI≥45。
临床怎么用
- 可依据四个术前因素评估转化手术候选者的预后风险,辅助治疗排序和患者选择。
局限性
- 结论需外部验证以确认其普遍适用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To identify prognostic factors, including preoperative treatment duration, among patients who underwent conversion surgery (CS) for unresectable locally advanced pancreatic cancer (UR-LAPC). BACKGROUND: While CS has been increasingly adopted for UR-LAPC, optimal perioperative strategies remain controversial. METHODS: This multicenter study included 465 UR-LAPC patients who underwent CS following preoperative chemotherapy with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP) from 2015 to 2020 at 84 Japanese institutions. RESULTS: Median overall survival (OS) from treatment initiation was 43.8 months with a 5-year survival rate of 37.2%. A prognostic cutoff for preoperative treatment duration was identified at 6.1 months using maximally selected rank statistics. Patients receiving >6 months of preoperative treatment (n=350) demonstrated significantly better OS (50.4 vs. 29.7 mo) and recurrence-free survival (RFS) (15.6 vs. 9.1 mo) compared with those receiving ≤6 months (n=115, both P<0.001). Multivariate analysis identified four independent preoperative prognostic factors: treatment duration >6 months, FFX-based regimens, normal tumor markers (CA19-9 and CEA), and a prognostic nutritional index ≥45 before CS. These four preoperative factors enabled clear prognostic stratification: patients with ≥3 factors showed significantly improved survival compared with those with ≤2 factors (HR 0.44, P<0.0001; 5-year OS: 59.8% vs. 26.3%). CONCLUSIONS: The combination of four preoperative prognostic factors may enable risk stratification among patients undergoing CS for UR-LAPC. These findings may help inform treatment sequencing and patient selection, although external validation is needed to confirm their generalizability.
引用
- Yasuda S, Satoi S, Takami H, et al. Clinicopathological Factors on Survival after Conversion Surgery for Unresectable Locally Advanced Pancreatic Cancer: A Nationwide Study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. Ann Surg. 2026. PMID: 41559871. doi:10.1097/SLA.0000000000007012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。